Suppression of a university scientist's findings about a common thyroid drug by a company that paid for the research has raised serious questions about how the growing link between industry and academia affects the reliability of information provided to doctors and the public about drugs and other medical therapies.
Experts see bias in drug data tied to research sponsorship.